Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 121 clinical trials
Featured trial
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.

  • 0 views
  • 16 May, 2022
  • 131 locations
Featured trial
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.

  • 0 views
  • 17 May, 2022
  • 101 locations
Featured trial
BRIDGE: Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery

BRIDGE: Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery

  • 92 views
  • 25 Mar, 2021
  • 1 location
A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

from taking TAK-079 at three different dose levels. Another aim is to learn if TAK-079 can increase the platelet count in people with ITP. In addition to receiving stable background therapy for

  • 3 views
  • 02 May, 2022
  • 8 locations
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery

As tranexamic acid (TXA) becomes more prevalent, all patients are receiving the same dose and method of delivery regardless of their pre-operative risk of transfusion. Therefore, the aim of the study is to determine whether or not repeated dosing of oral or different method of delivery like intravenous (IV) TXA …

  • 0 views
  • 23 Mar, 2022
  • 1 location
Niraparib Combined With Radiotherapy in rGBM

platelet count 150,000/L) or 200mg/day (body weight <77Kg or baseline platelet count <150,000/L), combined with radiotherapy (total dose 55Gy), follow-up Time 1 year. Until the patient has disease

  • 1 views
  • 02 Feb, 2021
  • 1 location
Eltrombopag Plus Diacerein vs Eltrombopag in Adult ITP

Primary immune thrombocytopenia (ITP) is an autoimmune bleeding disorder with low platelet count. As the first choice of the second-line treatment of ITP, thrombopoietin receptor agonist (TPO-RA

eltrombopag
platelet count
  • 1 views
  • 19 Jun, 2021
  • 1 location
NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. (NIRAPK)

predictive factors leading to hematologic toxicity were a weight <77kg and an initial platelet count <175 G/L. However, it seems more complex as 50% of patients with an initial weight between 58 and

  • 0 views
  • 05 May, 2022
Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome

This is a prospective, open-label, randomized, two-arm clinical trial conducted to evaluate the safety and efficacy of romiplostim in comparison with eltrombopag in the treatment of thrombocytopenia in patients with Wiskott-Aldrich syndrome

  • 6 views
  • 04 Mar, 2022
  • 1 location
Anti-BCMA CAR T-Cell Therapy for R/R ITP

This is a prospective, single-center, open-label, single-arm study, to evaluate the efficacy and safety of Anti-BCMA chimeric antigen receptor T cell therapy(BCMA CAR-T)for patients with relapse/refractory Immune thrombocytopenia(R/R ITP).

  • 0 views
  • 19 Apr, 2022
  • 1 location